Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy | Zendy

Katja Haemmerli Keller | Zendy; Christoph Daniel | Zendy; Harald O. Schöcklmann | Zendy; Karlhans Endlich | Zendy; Dontscho Kerjaschki | Zendy; Richard J. Johnson | Zendy; Christian Hugo | Zendy

Open Access

Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy

Author(s) -

Katja Haemmerli Keller,

Christoph Daniel,

Harald O. Schöcklmann,

Karlhans Endlich,

Dontscho Kerjaschki,

Richard J. Johnson,

Christian Hugo

Publication year - 2006

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl340

Subject(s) - everolimus , medicine , thrombotic microangiopathy , in vivo , cancer research , pharmacology , biology , microbiology and biotechnology , disease

Everolimus is a potent immunosuppressant used in renal transplant therapy, but its effects on renal endothelial cell regeneration after injury are unknown. The effects of an everolimus therapy were investigated in a model of renal thrombotic microangiopathy (TMA) with specific endothelial cell (EC) injury in the rat in vivo as well as in glomerular ECs in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research